RecruitingNot ApplicableNCT03392415

The NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion

The NOrdic-Baltic Randomized Registry Study for Long-term Clinical Evaluation of Adjunction of PCI to Optimal Medical Therapy in Chronic Total Coronary Occlusion


Sponsor

Leif Thuesen

Enrollment

2,000 participants

Start Date

Jun 1, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

Randomized registry for the study of CTO PCI as adjunction to optimal medical therapy.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • ≥1 CTO lesion amenable to PCI.
  • Stable and stabilized coronary artery disease
  • Symptoms (angina pectoris or shortness of breath) and/or signs of reversible perfusion defect by SPECT, PET or MR and/or angiographic/echocardiographic indication of reversible ischemia.
  • CTO lesion in a major coronary vessel supplying a significant myocardial territory (vessel diameter usually ≥3mm).

Exclusion Criteria5

  • Expected survival \<1 year.
  • Renal failure on dialysis.
  • Stable non-CTO lesions treated within one month.
  • Declined informed consent.
  • Regarding CMR: allergy to contrast medium, severe obesity, claustrophobia and certain metallic implants

Interventions

PROCEDURECTO PCI

attempted percutaneous coronary intervention of the chronic total coronary occlusion


Locations(1)

Aalborg University Hospital

Aalborg, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03392415


Related Trials